European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
Approval represents critical advancement in early intervention for multiple myeloma
SAN DIEGO, July 23, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma.
'This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma,' said Dr. Helen Torley, President and CEO of Halozyme. 'We are pleased that the new treatment paradigm addresses the critical needs of people living with this complex blood disease.'
SMM is an asymptomatic intermediate disease state of multiple myeloma where abnormal cells can be detected in the bone marrow. The current standard of care for SMM, even in high-risk cases, is active monitoring (or 'Watch and Wait') to track for signs of biochemical progression and/or end-organ damage. This means therapeutic intervention is only offered when the disease progresses.
The EC approval is supported by data from the Phase 3 AQUILA study (NCT03301220), evaluating the efficacy and safety of fixed-duration monotherapy daratumumab SC compared with active monitoring in those with high-risk SMM. For more information on the study and its findings, please view Johnson & Johnson's press release issued on July 23, 2025.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@halozyme.com
Sydney CharltonTeneo917-972-8407sydney.charlton@teneo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for PrBuccolam® in Canada and announces its approval by Health Canada
MONTREAL, Aug. 4, 2025 /CNW/ – Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, headquartered in Düsseldorf, Germany. Under the terms of the agreement, Pendopharm® will be responsible for the commercialization of Buccolam®(Midazolam Hydrochloride Oromucosal Solution) in Canada. Buccolam® is indicated for the treatment of prolonged, acute, convulsive seizures in children. Pendopharm® is pleased to announce that Health Canada has approved Buccolam®. About Epilepsy Epilepsy is a chronic neurological disorder characterized by recurrent seizures of various types and severity. These seizures result from abnormal electrical activity in the brain and can be triggered by a range of factors, including structural abnormalities, brain inflammation, physical injury, trauma, infection, or unknown causes. It is estimated that the underlying cause of epilepsy remains undetermined in up to 50% of patients diagnosed with epilepsy. 1 Nearly 1 out of 100 Canadians live with epilepsy, and approximately 13% of them are children and youth.1 Despite treatment with anti-seizure medications, some patients may experience prolonged acute convulsive seizures which require immediate intervention. Early treatment of acute seizures is critical to prevent escalation and improve patient outcomes.2,3 Benzodiazepines, are considered first-line therapy for managing prolonged seizures.4 Buccolam® is an oromucosal solution of midazolam (a benzodiazepine) supplied in a ready-to-use, pre-filled syringes for buccal (absorbed in the mouth) administration.5 'Prolonged convulsive seizures in pediatric patients can have significant short- and long-term impacts', said Dr. Aris Hadjinicolaou, Pediatric Neurologist at CHU Sainte-Justine. 'Having access to a ready-to-use, on-label medication could facilitate timely intervention during seizures and may decrease the need for emergency medical services'. 'This partnership represents Pendopharm's commitment to bringing medicines that address unmet medical needs to Canadian patients,' said Jad Isber, Vice President & General Manager of Pendopharm®. 'We look forward to working with Canadian neurologists and pediatricians to make Buccolam available to all patients who may benefit from it.' Dr. Maximilian von Wülfing, Chief Operating Officer of Neuraxpharm, said: 'Through its network of strategic partnerships around the world, Neuraxpharm is committed to expanding access to market-leading medicines. Our collaboration with Pendopharm further strengthens our position as a global CNS specialist enabling us to deliver an epilepsy treatment designed to reduce hospitalizations and provide support to patients and their caregivers.' About Pendopharm® Pendopharm, specialty division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm® has extensive experience and knowledge to successfully manage its growing product portfolio. For more information, please visit For media inquiries, please contact MediaInquiries@ © 2025 Pendopharm, division of Pharmascience Inc. All rights reserved. About Pharmascience Inc. Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience Inc.'s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients' needs. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions. The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit For more information, please contact: Neuraxpharm@ Pendopharm® and Design are registered trademarks owned by Finchley Research and Development Inc. Buccolam® is a registered trademark owned by Neuraxpharm, used under license by Pendopharm, a division of Pharmascience Inc. References: What is epilepsy? — Epilepsy Canada Epilepsie – consulted June 25th, 2025 Standard of Care and Role of Rescue Medications in Epilepsy Epilepsy Treatment | Treating Seizures | Epilepsy Foundation Seizure Rescue Medications | Types of Epilepsy Medications – consulted June 25th, 2025 Buccolam® Product Monograph. July 2025. Epilepsy in Canada – (gov Canada statistics) – consulted June 25th, 2025
BusinessToday
17 hours ago
- BusinessToday
PGMall Marks 8th Anniversary With First-Ever Summit
Homegrown e-commerce platform PGMall marked its eighth anniversary by hosting its inaugural PGMall Summit 2025, themed 'From Malaysia, For Malaysians' at Pullman KLCC. The event gathered more than 350 sellers and ConsuMerchants, highlighting the platform's role in empowering local businesses and digital entrepreneurs. Founded in 2017 as the e-commerce arm of Public Gold Group, PGMall differentiates itself with a flat 5% transaction fee, among the lowest in Malaysia, eschewing layered commissions and hidden charges. Dato' Seri Louis Ng, Founder & Executive Chairman of Public Gold Group 'PGMall is more than just an online marketplace. Our mission has always been about empowering sellers and consumers alike with tools to succeed in the digital economy —without the burden of high commissions on sellers,' said Dato' Seri Louis Ng, Founder and Executive Chairman of Public Gold Group. The platform's ConsuMerchant® Sharing Economy model has attracted over 2 million active shoppers and 30,000 sellers nationwide. Its Forever Cashback programme offers users up to 3.5% cashback through a referral-based reward system. 'Our sellers and ConsuMerchants are the foundation of this platform,' said PGMall Chief Operating Officer Jerry Ng, adding that the summit is aimed at strengthening collaboration with stakeholders. Awards were presented to outstanding performers in both the Seller and ConsuMerchant categories, including Top Growth Seller, Top Preferred Seller, Top Choice Seller and awards for personal and group sales achievements. PGMall reaffirmed its commitment to building an inclusive digital marketplace that prioritises long-term growth for sellers and consumers. The company plans to expand its footprint nationally and regionally, maintaining its focus on transparency and sustainable practices.
Daily Express
2 days ago
- Daily Express
Sabah needs new Department of Mineral Mining: Any decision on developing Sabah's mineral wealth must be in the interest of Sabahans and the State
Published on: Sunday, August 03, 2025 Published on: Sun, Aug 03, 2025 By: Tengku Datuk Fuad Tengku Ahmad Text Size: FOLLOWING on last week's article ( 'Bumi Suria is hoo-ha over nothing'; Daily Express 27.7.2025 ), it is timely to analyse and discuss some of the reforms necessary to advance Sabah's mineral mining administration and policies. This article will explore some administrative reforms which should be implemented to both modernise and clarify the decision-making process in respect of mining rights in Sabah. To start, no discussion concerning Sabah mining can proceed without first considering the role and functions of Sabah Mineral Management Sdn Bhd ('SMM'). SMM was incorporated in 2006 under the name Sabah Capital Sdn Bhd , as a sendirian berhad (a private company limited by shares) with a total paid-up capital of RM12 million. As of 24.7.2025, SMM's nature of business is listed as 'Investment Holding' . In 2021, the company changed its name officially from Sabah Capital Sdn Bhd to Sabah Mineral Management Sdn Bhd . From this, a few things stand out. Why is SMM's nature of business listed as 'Investment Holding' when the company holds itself out a government-linked company whose purpose is to facilitate and manage all mining and mineral development in Sabah? Second, it is unclear how a private limited company can seemingly exercise governmental powers in assessing and approving mining permits and licences issued under the Mining Ordinance 1960 ('MO')? Third, it is curious why SMM is not located closer to the Lands and Survey Department or the Chief Minister's office since both exercise decision-making powers under the MO? Finally, what advantages are there in outsourcing to SMM the mining licence and permit approvals process? Sabah Mineral Management Sdn Bhd is a government-linked company ('GLC') A company search reveals that SMM is a wholly owned subsidiary of The Chief Minister, Incorporated ('CMI'). CMI is a special purpose corporation created under the Chief Minister (Incorporation) Ordinance which enables the Sabah Government to hold assets through the office of the Chief Minister as if the same were a company. This alone shows that SMM is indeed a GLC. Moreover, the Board of SMM includes the Chief Minister, the Chief Conservator or Forests, The Secretary of Natural Resources, the State Attorney-General, State Secretary and other senior government officials. On its surface, it appears that SMM seems to function as a quasi-government department with one important difference: SMM is still a sendirian berhad and is subject to the provisions of the Companies Act 2016. It is not a government department and is not subject to the protections provided under the Government Proceedings Act 1956 or the Public Authorities Protection Act 1948, among others. More importantly, the purpose and functions of a private limited company are very different from those of a government department. Can / should SMM assess and approve permits and licences under the Mining Ordinance ('MO')? It is easy to assume that it is lawful for SMM to exercise governmental decision-making powers simply because it is owned by the Sabah government and where the Chief Minister and other senior officials sit on SMM's board. A layman would be forgiven for asking what is the difference between a decision made by SMM and one made by the Sabah government when both are comprised of the Chief Minister and other relevant government officials? The difference is this: The Companies Act requires the board of private limited companies to make decisions in the interest of the company whereas a government authority or department is constitutionally required to make decisions in the interests of the State of Sabah and its people. So, every time SMM's board holds a meeting, Malaysian company law requires that the board makes decisions in the financial interests of SMM and not the people of Sabah. Failure to observe this can attract legal consequences. This is an important point to observe. The Sabah Government holds the state's mineral resources on trust for the benefit of the people of Sabah. Therefore, any decision concerning the development of Sabah's mineral wealth must be made in the interest of Sabahans and the state – the Chief Minister and his officials must not be constrained from doing so by the restrictive requirements of SMM's board as required by the provisions of the Companies Act. Apart from this apparent inconsistency between corporate and governmental duties and objectives, another issue arises: under what authority does SMM function? From press reporting and other inquires, it appears that SMM's function is to facilitate and manage the mining permit and licence application process in Sabah. Put simply, if you want a mining permit or licence in Sabah, you must apply through SMM. But the question remains, from where and how does SMM derive its powers? SMM does not have statutory recognition The MO does not mention – at all – SMM or any other private corporate body as having a role in the application for or issuance of mining permits or licences. Section 6 of the MO empowers the Director of Lands and Survey to issue mining licences to any person with the approval of the Chief Minister (being the Minister in charge of natural resources). Section 4 MO operates identically in respect of the issuance of mining permits. The MO does not, however, provide for any delegation of the Chief Minister's duties or functions in respect of approving mining permits or licences. Unless specifically permitted by legislation, a Minister or other official cannot delegate their duties, the exercise of their discretion or powers to another person or entity. This would include SMM. The only exception is where the Minister authorises a governmental official to perform some of his functions or duties where the Minister is ultimately accountable to the State Legislative Assembly for the actions of said government official. Additionally, the Delegation of Powers Enactment , 1963 does not assist SMM. Section 3 permits the Chief Minister to delegate the performance of his duties to any person described by name or office. 'Any person described by name or office' in this context means any Sabah government official or governmental office. It does not mean any non-governmental official or entity since, as stated above, the conduct and actions of officials acting under Ministerial power must always remain answerable to the Legislative Assembly. Additionally, and for completeness, there is no Gazette announcing that the Chief Minister has delegated his functions and powers under the MO to SMM as would be required by Section 8 of the Delegation of Powers Enactment. This raises another inconsistency. SMM is purportedly concerned with the development of mineral and mining matters in Sabah. This would clearly designate SMM as being subject to the Minister in charge of natural resources which, is the Chief Minister. And yet, a search of the Warta Kerajaan Negri Sabah reveals that SMM is designated as coming under the Sabah Minister of Finance, who, does not have any direct duties or functions under the MO (See: Warta Kerajaan Negri Sabah, 18 July, 2024). SMM – Cannot make decisions on the Chief Minister's behalf To be fair to SMM, it can be argued that the company only plays an advisory role where it scrutinises mining permit and licence applications and makes a recommendation to the Chief Minister for approval. However, in practice, it is widely perceived that SMM acts as an approving authority and that mining permits and licences will not be issued unless approved by SMM's board of directors. This would imply that mining licence and permit applications are considered and assessed by SMM. The Chief Minister, therefore, must not treat the conclusions of SMM as being final or binding on him or on any exercise of his discretion under the MO. Instead, the Chief Minister should (and does) consider each mining permit or licence application and make a decision based on the merits – the Chief Minister should not appear to delegate the exercise of his discretion to SMM. Moving Forward – Proposed Reforms So, in short, SMM does not have any official statutory or ministerial authority to assess or recommend for approval, mining permit or licence applications in Sabah. SMM, however, has de facto authority because the Sabah Government appears to treat SMM as if it were a government department when in fact its status as a private limited company is – at times - legally inconsistent with that of a government department. Therefore, it is in the best long-term interests of Sabah for the GRS-lead government to create a new Department of Mineral Mining headed by a Commissioner or head of department (an official on par with the Chief Conservator of Forests). By subsuming SMM's de facto duties and functions, it is argued that a new Mineral and Mining Department would not only promote greater transparency in the mining permit and licence application process but moreover, result in more accountability and public consultation in respect of mineral mining policy in Sabah. This would bring the development of mineral mining in Sabah in line with the development and management of the state's forest and timber resources. The creation of a new mining and minerals department must also be accompanied by a modernisation of the Mining Ordinance 1960 where its provisions should be harmonised with the environmental and forestry protections contained in the Forest Enactment 1968. This whole-sale structural and legislative reform of Sabah's mining and mineral management sector should be made a priority under the GRS-lead government since – as recent news on the matter shows – the current state of affairs is no longer sustainable or in the best interests of Sabah. Tengku Datuk Fuad Tengku Ahmad Tengku Fuad is a senior lawyer specialising in commercial and public law and has, and continues to, act for the Sabah Government in complex cases. In 2021 Tengku Fuad was appointed as a member of the Federal Government's Special Task Force to review legal matters related to the sovereignty of Batu Puteh, Middle Rocks and South Ledge and, in 2022, was also appointed to the Federal Government's Special Task Force to resist the Sultan of Sulu's (heirs) claim against Malaysia. Prior to establishing his firm, Tengku Fuad served as a public company director and was involved in the corporate sector. The views expressed here are the views of the writer and do not necessarily reflect those of the Daily Express. If you have something to share, write to us at: [email protected]
